Table 1.
Metastatic PPGL | Non-Metastatic PPGL | p | |
---|---|---|---|
(n = 18) | (n = 27) | ||
Age at Initial Diagnosis
(median, range) |
39 (18–65) | 58 (17–80) | 0.01 |
Sex | |||
Female | 10 | 18 | 0.537 |
Male | 8 | 9 | |
Primary Tumor Location | |||
Adrenal | 3 | 15 | 0.012 |
Extra-adrenal | 15 | 12 | |
Abdominal | 10 | 10 | |
Head and neck | 2 | 0 | |
Bladder | 3 | 2 | |
Functional Status | |||
Adrenergic | 1 | 12 | 0.012 |
Noradrenergic | 8 | 4 | |
Silent or Dopaminergic | 7 | 9 | |
Not available | 2 | 2 | |
Diabetes Mellitus | 7 | 5 | 0.175 |
Hypertension | 10 | 15 | 1 |
Ki-67 LI | |||
≥3% | 14 | 9 | 0.006 |
<3% | 4 | 18 | |
Tumor Size | |||
≥50 mm | 14 | 13 | 0.065 |
<50 mm | 4 | 14 | |
123I-MIBG Uptake | |||
Positive | 9 | 24 | 0.007 |
Negative | 6 | 1 | |
Not available | 3 | 2 | |
SDHB Staining | |||
Positive | 6 | 26 | <0.001 |
Negative | 12 | 1 |
Abbreviations: PPGL, pheochromocytoma and paraganglioma; Ki-67 LI, Ki-67 labeling index; MIBG, Metaiodobenzylguanidine; SDHB, succinate dehydrogenase subunit B.